USD 135.93 Billion
Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product Type (Monoclonal Antibodies [Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies], Vaccines (Prophylactic Vaccines), By Cancer Type (Lung Cancer, Breast Cancer, Multiple Myeloma), By End-User (Hospitals, Clinics & Others), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2296 |
Region:
Global |
Published Date: September, 2024
Pages:
157
|Tables:
120
|Figures:
69
Cancer Immunotherapy Market Insights
Cancer Immunotherapy Market size was valued at USD 135.93 Billion in 2023 and is poised to grow from USD 147.35 Billion in 2024 to USD 280.93 Billion by 2032, growing at a CAGR of 8.4% during the forecast period (2025-2032).
Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancer. Cancer immunotherapy is used in different types of cancers such as melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. Immunotherapy works by directing the immune system toward cancer-specific targets, activating the immune system to mobilize the target, and triggering a response capable of destroying cancer cells.
There are many factors, such as increase in healthcare expenditure, rise in incidence of cancer, surge in access to medical insurance, and surge in technological advancements in cancer treatment therapies expected to propel the growth of the global cancer immunotherapy market. According to statistics given by national cancer institute in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people passed away due to the disease. This surge in the incidences of cancer propel the growth of the industry in the coming years. Increase in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period. However, the factors such as stringent regulations related to cancer immunotherapy are anticipated to hinder the growth of the cancer immunotherapy market. Government have better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market. Also, high product developmental cost is anticipated to impede the growth of the cancer immunotherapy market.
US Cancer Immunotherapy Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Hospitals & Clinics
Fastest Growth
Cancer Research Centers
Growth Rate
8.4% CAGR
Global Cancer Immunotherapy Market ($ Bn)
Country Share for North America Region (%)
To get more reports on the above market click here to Buy The Report
Cancer Immunotherapy Market Segments Analysis
Global Cancer Immunotherapy Market is segmented by Product Type, Application, End user, and region. Based on Product Type, the market is segmented into Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types. Based on End user, the market is segmented into Hospitals, and Clinics & Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Analysis by Product Type
In terms of product type, the demand for Cancer Immunotherapy market is segmented into Monoclonal Antibodies, Immunomodulators, and Oncolytic Viral Therapies & Cancer Vaccines. Monoclonal Antibodies segment led the market and accounted for the largest revenue share of in 2023. Increasing investment for R&D of monoclonal antibodies—such as bispecific antibodies, conjugated monoclonal antibodies, and naked antigen binding antibodies—has opened new avenues for the growth of companies in the oncology therapeutics space. New-age monoclonal antibodies are designed to impart or possess adaptive immunity, antibody dependent cellular toxicity, and antigen specificity. Monoclonal antibodies are being largely studied for their therapeutic effects against various types of cancers.
Oncolytic Viral Therapies and Cancer Vaccines is anticipated to witness a significant market growth over the forecast period. The development of cancer vaccines, which are subject to significant obstacles such as lack of immunogenicity and immunosuppression effects within the tumor microenvironment, must succeed. According to American Association for Cancer Research in June 2023, the US Food and Drug Administration has only approved a limited number of therapeutic vaccines. Some of the choices available include sipuleucel-T (Provenge), which is a vaccine made from cells and is authorized as a treatment for unconventional prostate cancer, laherparepvec talimogene (Imlygic or T-VEC), which is a vaccine derived from a virus and is approved for Bacillus Calmette Guerin and treating metastatic melanoma, a weakened strain of bacteria used to prevent the recurrence of early-stage bladder cancer following surgery. These aspects are boosting the market.
Analysis by End-User
Based on end-user, the market is segmented into Hospitals & Clinics, Cancer Research Centers, and Others. Hospitals & Clinics segment accounted for the largest revenue share in 2023. In addition to rising incidence of diseases, increased treatment rate, higher awareness and malignancy diagnosis as well as a large number of hospitals offering immunotherapies is contributing to an increase in the number of patients treated. To treat cancer, hospitals are adopting immunotherapies. According to the National Cancer Institute article published in April 2023, in the U.S. 25% of patients died in a hospital, with 62% hospitalized at least once in the last month of life for the cancer treatments.
Cancer Research Centers segment is estimated to register a significant CAGR over the forecast period. Increased research on cancer and ongoing supportive activities carried out by government or national organizations in the form of grant funding have contributed to segment growth with a view to stimulating demand. According to Becker's Healthcare article published in November 2023, to expand research into cancer, Texas Oncology has recently revealed its Amarillo Comprehensive Cancer Center, a state-of-the-art facility representing a significant investment of USD 150 million. This cutting-edge center is poised to enhance cancer care, providing advanced and comprehensive services in the Amarillo region. These aspects are boosting the market.
Global Cancer Immunotherapy Market Analysis by End Use
To get detailed analysis on other segments, Request For Free Sample Report
Cancer Immunotherapy Market Regional Insights
North America dominated the market and accounted for highest market share in 2023, driven by rising patient awareness, high disease burden, proactive government measures, technological advancements, and improvements in healthcare infrastructure. The presence of key players in this region is a key propeller of market growth. According to Elsevier Ltd. article published in April 2023, The US National Cancer Institute has published its expected national cancer plan, a roadmap, and call to action on improving all stages of care for those suffering from cancer, including prevention, detection, diagnosis during the course of treatment and recovery.
Asia Pacific is anticipated to witness the fastest CAGR in the global market. One of the primary factors driving this growth is an increase in the elderly population, a high number of patients with targeted diseases and improved healthcare infrastructure. Furthermore, the expansion of this region is being aided by an increasing legal acceptance of immunotherapeutics in these regions. According to the MJH Life Sciences article published in November 2023, durvalumab (Imfinzi) plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer is approved by China’s National Medical Products Administration.
Global Cncer Immunotherpay Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Cancer Immunotherapy Market Dynamics
Cancer Immunotherapy Market Drivers
Growing Cancer Incidences
- The expansion of the global cancer immunotherapy market is fueled by the rising worldwide occurrence of diverse cancers. This surge in cancer prevalence is a key factor driving the need for inventive and efficient treatment strategies. With cancer remaining a primary cause of global morbidity and mortality, encompassing various types such as lung, breast, colorectal, melanoma, and hematological malignancies, the demand for innovative solutions is paramount. This situation highlights the significance of developing novel approaches to address the growing burden of cancer globally.
Technological Development in Cancer Diagnosis and Treatment
- The advent of immune-based therapies, particularly immunotherapy (IO), has heralded a transformative era in cancer therapy. IO has reshaped treatment paradigms, offering a survival benefit compared to conventional chemotherapy while maintaining a manageable toxicity profile. Immunotherapy extends the lifespan of cancer patients, serving as a secondary alternative when standard treatments are unsuitable, such as in the elderly population.
Cancer Immunotherapy Market Restraints
Expensive Treatment
- The prevalence of cancer has increased rapidly in the last decade so research and developments associated to cancer treatment has become an important subject matter in medical sciences. The studies related to drug manufacturing and immunotherapies for cancer treatment is very high. Thus, with increase in manufacturing and testing process of immunotherapies, the treatment cost becomes very high for patients which in turn restrains the market growth. Moreover, there are several side effects of immunotherapy such as swelling, skin rashes, heart palpitations, a stuffy head and some others. Thus, these side effects tend people to avoid immunotherapy that in turn restrains the growth of the cancer immunotherapy market.
Growing Prevalence of Immune-Related Cases
- The emergence of immune-related adverse events (irAEs) creates a significant concern in the domain of immunotherapy. This is presenting a substantial challenge in terms of their effective management. Since immunotherapeutic interventions function by activating the immune system, the inadvertent occurrence of side effects, termed irAEs, constitutes an inherent risk. These adverse events have the potential to impact diverse organs and systems throughout the body, necessitating vigilant monitoring and swift intervention.
Request Free Customization of this report to help us to meet your business objectives.
Cancer Immunotherapy Market Competitive Landscape
The market is moderately fragmented with the presence of dominant market players along with several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending money on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.
Cancer Immunotherapy Market Top Player’s Company Profiles
- Amgen Inc. (US)
- AstraZeneca (UK/Sweden)
- Bayer AG (Germany)
- Bristol-Myers Squibb (US)
- Eli Lilly and Company (US)
- Janssen Global Services, LLC (Johnson & Johnson) (US)
- Merck & Co., Inc. (US)
- Novartis (Switzerland)
- Pfizer Inc. (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Gilead Sciences, Inc. (US)
- GlaxoSmithKline plc (UK)
- AbbVie Inc. (US)
- Regeneron Pharmaceuticals, Inc. (US)
- Adaptimmune Therapeutics plc (UK)
- Incyte Corporation (US)
- Bluebird bio, Inc. (US)
- BioNTech SE (Germany)
- Immunocore Limited (UK)
- CureVac N.V. (Germany)
- BeiGene, Ltd. (China)
- Zymeworks Inc. (Canada)
Cancer Immunotherapy Market Recent Developments
- In May 2024, The FDA has given its approval to Amgen for an immunotherapy to treat cancer. This immunotherapy is named IIMDELLTRA and can be used to treat adult patients suffering from extensive-stage small lung cancer (ES-SCLC).
- In March 2024, Bristol Myers Squibb received approval from the FDA for Breyanzi. Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy that helps in treatment of patients suffering from relapsed or refractory small lymphocytic lymphoma and chronic lymphocytic leukemia.
- In March 2023, the FDA gave approval of Merck KGAA’s Bavencio. This is an anti-programmed death ligand-1 (PD-L1) antibody therapy that is efficient for treatment of advanced renal cell carcinoma and metastatic Merkel cell carcinoma.
Cancer Immunotherapy Key Market Trends
- Diversified Immunotherapies Solutions: There is rapid growth and development in the field of medical sciences. The number of cancer patients has also increased across the world that tend doctors, scientists, researcher and others to develop effective therapies for cancer treatment. Recently, researchers have found out a new process of extracting immunotherapy drugs using peptide linkages inside the human body. This method was first developed by the researchers of the University of Texas and MD Anderson Cancer Center and is considered to be an effective method for immunotherapy drug development for cancer treatment.
- Rising Demand for Combination Therapies: An observable shift in cancer treatment is the growing focus on combination therapies. It is offering a compelling pathway for heightened effectiveness and broader application. This inclination involves investing into the development of strategies that combines various immunotherapies or incorporate immunotherapy with traditional treatments. The fundamental principle of these combinations is to use the individual strengths of each therapeutic approach.
Cancer Immunotherapy Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, increasing prevalence of cancer among the population and rising number of deaths associated with cancer disease is boosting the demand for this market. The significant increase in the disease burden on the population is expected to drive the global market during the forecast period. Rising approval of novel immunotherapies is expected to propel the market growth over the forecast period.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 135.93 Billion |
| Market size value in 2032 | USD 280.93 Billion |
| Growth Rate | 8.4% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Cancer Immunotherapy Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Cancer Immunotherapy Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Cancer Immunotherapy Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Cancer Immunotherapy Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Cancer Immunotherapy Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Cancer Immunotherapy Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
